Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | AGER | Q15109 | 1/20 | 0.57 |
| ▸ | GLB1 | P16278 | 1/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.52 |
| ▸ | CTRC | Q99895 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2969737 | 0.86 | ESR1 (1.00) | ESR1ESR2ALOX15KEAP1IDO1 | |
| SCHEMBL36454 | 0.86 | ESR1 (1.00) | ESR1ESR2ALOX15KEAP1IDO1 | |
| SCHEMBL30330993 | 0.86 | CYP2A6 (0.57) | ESR1ESR2ALOX15IDO1TAAR1 | |
| SCHEMBL3334615 | 0.86 | CYP2A6 (0.57) | ESR1ESR2ALOX15IDO1TAAR1 | |
| SCHEMBL10355578 | 0.84 | ESR1 (0.74) | ESR1ESR2ALOX15AGERGLB1 | |
| SCHEMBL17443 | 0.83 | — | — | |
| SCHEMBL6118114 | 0.83 | ALOX15 (1.00) | ESR1ESR2ALOX15AGERGLB1 | |
| SCHEMBL15809732 | 0.82 | ALOX15 (0.65) | ESR1ESR2ALOX15AGERGLB1 | |
| Potassium SCHEMBL31030244 | 0.80 | — | — | |
| SCHEMBL28429380 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024008909-A1 | INHIBITORS OF CORONAVIRUS | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-11 | — | — | WO | disclosed |
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
| EP-3731840-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | Orfan Biotech Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| CN-103974981-B | Hardening resin composition, curable resin formed body, cured resin formed body and their manufacture method and duplexer | LINTEC CORP. (JP) | 2016-05-18 | — | — | CN | disclosed |
| US-9139567-B2 | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-9139567-B2 | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-9139567-B2 | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| EP-2734516-B1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INT (DE) | 2015-06-17 | — | — | EP | disclosed |
| EP-2734516-B1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INT (DE) | 2015-06-17 | — | — | EP | disclosed |
| CN-103201109-B | Gas-barrier film, process for producing same, member for electronic device, and electronic device | LINTEC CORP. (JP) | 2014-10-22 | — | — | CN | disclosed |
| WO-2007040681-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040682-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007008627-A2 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2007-01-18 | — | — | WO | disclosed |
| US-6242654-B1 | REACTING A PHENOLATE COMPOUND WITH AN ORGANIC FLUORINATING AGENT TO PREPARE A FLUORINE SUBSTITUTED AROMATIC COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-1013629-A1 | Preparation process of fluorine subsituted aromatic compound | Mitsui Chemicals, Inc. (JP) | 2000-06-28 | — | — | EP | disclosed |
| EP-0164638-B1 | PROCESS FOR THE PREPARATION OF POLY(ARYLENE SULFIDES) WITH FUNCTIONAL END GROUPS | BAYER AG (DE) | 1990-05-09 | — | — | EP | disclosed |
| US-4605732-A | Process for the production of polyarylene sulphides with functional end groups | BAYER AKTIENGESELLSCHAFT (DE) | 1986-08-12 | — | — | US | disclosed |
| EP-0164638-A2 | Process for the preparation of poly(arylene sulfides) with functional end groups | BAYER AG (DE) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | ESR1 2616/4885ESR2 1656/4885ALOX15 10/4885 |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | ESR1 2616/4885ESR2 1656/4885ALOX15 10/4885 |
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | PNPO, XDH, GLS | ESR1 4403/4885ESR2 4768/4885ALOX15 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.